Neurophet Showcases Alzheimer’s Imaging AI at ASNR 2025 to Expand Global Reach
At the 63rd Annual Meeting of the American Society of Neuroradiology (ASNR 2025), held in Philadelphia from May 17 to 21, Neurophet, a Korean medical AI company, presented the clinical potential of its advanced brain imaging solutions. Specializing in the diagnosis and treatment of brain diseases, the company used the event to highlight how its technologies are poised to support evolving Alzheimer’s treatment strategies.
A key focus of Neurophet’s participation was the presentation of Neurophet AQUA AD, its flagship software developed specifically for Alzheimer’s disease imaging. During the industry collaboration session, co-CEO Been Jun-kil introduced the software, emphasizing its ability to assist clinicians in monitoring the effectiveness, safety, and side effects of anti-amyloid antibody therapies such as Leqembi (lecanemab) and Kisunla (donanemab). As these treatments gain global traction, the need for precise imaging tools to assess therapy response and detect complications like amyloid-related imaging abnormalities (ARIA) is growing rapidly.
Neurophet AQUA AD addresses this need by leveraging quantitative analysis of MRI and PET scans, delivering crucial imaging insights required throughout the treatment process. This includes tracking ARIA, a known risk factor in immunotherapy for Alzheimer’s patients. The software is designed to provide real-time assessments that can guide therapeutic decisions and enhance patient safety. According to Been Jun-kil, the global adoption of Alzheimer’s therapies has placed ARIA monitoring at the forefront of clinical priorities. He noted that Neurophet AQUA AD is increasingly being recognized as a vital tool for imaging-based evaluation during drug therapy.
Beyond this key presentation, Neurophet also demonstrated its broader AI-driven imaging portfolio at the ASNR 2025 exhibition booth. This included Neurophet AQUA, a solution for analyzing neurodegeneration, and Neurophet SCALE PET, a software tool for quantitative PET imaging. These offerings underline the company's comprehensive approach to supporting neurological diagnosis and treatment with cutting-edge AI technologies.
Neurophet positioned ASNR 2025 not only as an opportunity to showcase its products but also as a strategic springboard for international expansion. The company aims to strengthen its collaborations with global pharmaceutical companies and leading neurologists, leveraging its proprietary software to play a larger role in clinical research and therapeutic decision-making worldwide. By aligning itself with emerging demands in the Alzheimer’s treatment space, Neurophet is poised to contribute significantly to both drug monitoring and broader neurological care.
Through its presence at the conference and growing recognition of Neurophet AQUA AD, the company is reinforcing its status as a key player in the intersection of AI and neuroimaging, with ambitions to make its technologies integral to clinical workflows and future innovations in brain disease management.